Picture Demy-Colton BioFuture 2024 NYC Game Changers 650x100px
Collaboration › Details

Bicycle Therapeutics–Goldman Sachs: investor conference, 202406 supply service Bicycle Tx at GS Annual Global Healthcare Conference


Period Period 2024-06-10
Region Region New York, NY
  Country United States (USA)
Organisations Partner, 1st Bicycle Therapeutics plc (Nasdaq: BCYC)
  Group Bicycle Therapeutics (Group)
  Partner, 2nd Goldman Sachs & Co. LLC
  Group Goldman Sachs (Group)
Products Product Goldman Sachs Annual Global Healthcare Conference 2024 Miami
  Product 2 Bicycles® platform (bicyclic peptides)

Bicycle Therapeutics plc. (6/3/24). "Press Release: Bicycle Therapeutics to Participate in Upcoming Investor Conferences". Cambridge & Boston, MA.

Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced that management will participate in the following investor conferences in June:

> Jefferies Global Healthcare Conference on Wednesday, June 5, 2024; fireside chat at 8:30 a.m. ET

> Goldman Sachs 45th Annual Global Healthcare Conference on Monday, June 10, 2024; fireside chat at 1:20 p.m. ET

> TD Cowen 2nd Annual Radiopharmaceutical Innovation Summit on Monday, June 17, 2024; fireside chat at 3:00 p.m. ET

Live webcasts of the fireside chats will be accessible in the Investor section of the Company’s website at Archived replays of the webcasts will be available following the fireside chat dates.

About Bicycle Therapeutics

Bicycle Therapeutics is a clinical-stage pharmaceutical company developing a novel class of medicines, referred to as Bicycle® molecules, for diseases that are underserved by existing therapeutics. Bicycle molecules are fully synthetic short peptides constrained with small molecule scaffolds to form two loops that stabilize their structural geometry. This constraint facilitates target binding with high affinity and selectivity, making Bicycle molecules attractive candidates for drug development. The company is evaluating zelenectide pevedotin, previously BT8009, a Bicycle® Toxin Conjugate (BTC®) targeting Nectin-4, a well-validated tumor antigen; BT5528, a BTC molecule targeting EphA2, a historically undruggable target; and BT7480, a Bicycle Tumor-Targeted Immune Cell Agonist® (Bicycle TICA®) targeting Nectin-4 and agonizing CD137, in company-sponsored clinical trials. Additionally, the company is developing Bicycle® Radio Conjugates (BRC™) for radiopharmaceutical use and, through various partnerships, is exploring the use of Bicycle® technology to develop therapies for diseases beyond oncology.

Bicycle Therapeutics is headquartered in Cambridge, UK, with many key functions and members of its leadership team located in Cambridge, Mass. For more information, visit

View source version on

Stephanie Yao
SVP, Investor Relations and Corporate Communications

Deborah Elson
Argot Partners

Record changed: 2024-06-05


Picture EBD Group BIO-Europe 2024 Stockholm BEU24 650x200px

More documents for Bicycle Therapeutics (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]


Picture EBD Group World of Partnering Opportunities 650x300px

» top